Inspire Medical Systems (INSP)
(Delayed Data from NYSE)
$191.48 USD
+5.13 (2.75%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $191.38 -0.10 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
F Value A Growth B Momentum B VGM
Company Summary
Minneapolis, MN-based Inspire Medical is a medical technology company focused on the development and commercialization of innovative, minimally-invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. A significant body of clinical data supports the safety and efficacy of Inspire therapy.
...
Company Summary
Minneapolis, MN-based Inspire Medical is a medical technology company focused on the development and commercialization of innovative, minimally-invasive solutions for patients with obstructive sleep apnea (OSA). Its proprietary Inspire system is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. The company has developed a novel, closed-loop solution that continuously monitors a patient’s breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. A significant body of clinical data supports the safety and efficacy of Inspire therapy.
Inspire therapy received premarket approval (PMA) from the FDA in 2014 and has been commercially available in certain European markets since 2011. Japan's Ministry of Health, Labour and Welfare approved Inspire therapy to treat moderate to severe OSA in 2018. Inspire therapy is indicated for patients with moderate to severe OSA who do not have significant central sleep apnea and do not have a complete concentric collapse of the airway at the soft palate level. Additionally, patients in the United States, Japan, and Singapore must have been confirmed to fail or be unable to tolerate positive airway pressure (PAP) treatments, such as continuous positive airway pressure (CPAP), and be 18 years of age or older, though there are no similar requirements for patients in Europe. Physicians have treated more than 60,000 patients with Inspire therapy at more than 1,300 medical centers across the United States, Europe and Asia.
FY23 at a Glance
In 2023, Inspire Medical reported revenues of $624.8 million, up 53.2% over FY22.
Inspire Medical derives revenues from two geographic sources — the United States (97% of net revenues, up 53.5% over FY22) and All other countries (3%, up 43%).
General Information
Inspire Medical Systems, Inc
5500 WAYZATA BLVD SUITE 1600
GOLDEN VALLEY, MN 55416
Phone: 844-672-4357
Fax: NA
Web: http://www.inspiresleep.com
Email: ezgiyagci@inspiresleep.com
Industry | Medical Info Systems |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/5/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.06 |
Current Year EPS Consensus Estimate | 0.75 |
Estimated Long-Term EPS Growth Rate | NA |
Exp Earnings Date | 11/5/2024 |
Price and Volume Information
Zacks Rank | ![]() |
Yesterday's Close | 186.35 |
52 Week High | 257.40 |
52 Week Low | 123.00 |
Beta | 1.31 |
20 Day Moving Average | 752,300.50 |
Target Price Consensus | 219.47 |
4 Week | 41.78 |
12 Week | 24.04 |
YTD | -5.87 |
4 Week | 35.86 |
12 Week | 15.25 |
YTD | -21.57 |
Shares Outstanding (millions) | 29.82 |
Market Capitalization (millions) | 5,710.32 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 254.55 |
Trailing 12 Months | 1,063.78 |
PEG Ratio | NA |
vs. Previous Year | 178.05% |
vs. Previous Quarter | 194.12% |
vs. Previous Year | 29.65% |
vs. Previous Quarter | 19.43% |
Price/Book | 8.95 |
Price/Cash Flow | NA |
Price / Sales | 8.09 |
6/30/24 | 1.03 |
3/31/24 | -2.82 |
12/31/23 | -3.93 |
6/30/24 | 0.88 |
3/31/24 | -2.40 |
12/31/23 | -3.38 |
6/30/24 | 9.25 |
3/31/24 | 7.93 |
12/31/23 | 7.60 |
6/30/24 | 8.35 |
3/31/24 | 7.25 |
12/31/23 | 7.17 |
6/30/24 | 0.85 |
3/31/24 | -2.38 |
12/31/23 | -3.39 |
6/30/24 | 0.85 |
3/31/24 | -2.38 |
12/31/23 | -3.39 |
6/30/24 | 1.21 |
3/31/24 | -2.13 |
12/31/23 | -3.19 |
6/30/24 | 21.40 |
3/31/24 | 19.44 |
12/31/23 | 19.39 |
6/30/24 | 2.55 |
3/31/24 | 3.13 |
12/31/23 | 4.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |
6/30/24 | 0.00 |
3/31/24 | 0.00 |
12/31/23 | 0.00 |